Try Karma Today

Opinion and analysis from a team of private investors for today’s most creative minds in business.

Try Karma Today

Join Karma Premium

Gain exclusive member access to industry briefs, market movements, and in-depth analysis of global economic shifts.

SpringWorks Therapeutics Scores $125M in Series B Financing Through Perceptive Advisors

On Our Radar: Deals we are paying attention to for their impact on industry.


Clinical-stage biopharmaceutical company SpringWorks Therapeutics, Inc. moved closer on April 1 to advancing medicines for patients with severe rare diseases and cancer when it closed a $125 million Series B preferred stock financing led by Perceptive Advisors.


SpringWorks launched in 2017 as a spinoff to Pfizer Inc. with $103 million Series A financing from Pfizer, Bain Capital, OrbiMed, and LifeArc.


The proceeds of the latest financing round will go toward SpringWorks’ two late-stage rare disease oncology programs. They are: nirogacestat, a gamma secretase inhibitor for the treatment of desmoid tumors, which received a Fast Track designation from the U.S. Food and Drug Administration in November; and PD-0325901, a MEK inhibitor for the treatment of neurofibromatosis Type 1-associated plexiform neurofibromas. The cash also will help the company’s expansion into new targeted oncology programs and future in-licensing opportunities and clinical collaborations in rare diseases and cancer.


Boxer Capital of Tavistock Group, HBM Healthcare Investments, BVF Partners, Surveyor Capital, Samsara BioCapital, ArrowMark Partners, GlaxoSmithKline , and Laurion Capital Management, and several other long-term institutional investors took part in the latest financing. In addition, all of SpringWorks’ existing investors participated.


Among SpringWorks’ competitors are CrownBio and Ultragenyx Pharmaceuticals.


Michelle Lodge is a New York-based writer whose work has appeared in Time, Fortune, Barron's, the Miami Herald, the British Medical Journal as well as on CNBC.com.

Join Karma Premium

Gain exclusive member access to industry briefs, market movements, and in-depth analysis of global economic shifts.

Related Content